Tuesday 13 October 2026
Export EDIT’s income statement to Excel — free account
Editas Medicine, Inc.
EDIT Healthcare Biotechnology
Editas Medicine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.5 million, up 25.4% from fiscal 2024. In the quarter to June 2026, revenue grew 232.3%, EPS grew 76.2% and free cash flow grew 40.7%, each against the same quarter a year earlier.
2.47
0.28
−10.18%
Follow EDIT
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
2 | 2 | 4 | 2 | 3 | 3 | 2 | 5 | 5 | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
(13.39) | (7.30) | (0.67) | (1.28) | 6.84 | 12.28 | 2.17 | 2.25 | 3.28 | 1.62 |
P/S ratio |
4.49 | 3.24 | 9.70 | 29.40 | 70.28 | 45.29 | 72.09 | 33.55 | 100.81 | 90.70 |
Altman Z″-Score (non-manufacturers) |
(29.91) | (14.20) | (4.23) | (3.54) | 3.11 | 1.07 | 0.95 | 1.59 | 1.69 | 0.42 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(5.00) | (2.06) | (34.09) | (13.71) | (51.91) | (102.47) | 36.08 | 807.45 | (55.20) | (40.14) |
Beneish M-Score |
(2.46) | 7.05 | (0.16) | 18.81 | (4.56) | 4.42 | 16.96 | (2.01) | (0.54) | (3.16) |
P/B ratio |
6.67 | 0.78 | 2.17 | 1.61 | 3.24 | 10.44 | 5.64 | 4.54 | 6.65 | 4.08 |
Price to Tangible BV |
6.67 | 0.78 | 2.17 | 1.61 | 3.24 | 10.44 | 5.64 | 4.54 | 6.65 | 4.08 |
EV/Sales |
1.67 | (4.11) | 5.98 | 13.58 | 51.98 | 41.21 | 51.40 | 23.01 | 79.27 | 65.89 |
EV/EBITDA |
0.00 | 0.53 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(0.41) | 0.63 | (3.54) | (1.51) | (8.11) | (20.79) | (25.95) | (16.08) | (115.56) | (7.94) |
EV/FCF |
(0.41) | 0.61 | (3.41) | (1.48) | (7.73) | (20.00) | (22.58) | (14.58) | (94.95) | (7.42) |
Quick Ratio |
3.50 | 3.71 | 5.27 | 5.81 | 10.67 | 7.01 | 7.63 | 10.28 | 8.99 | 5.60 |
Current Ratio |
3.54 | 3.75 | 5.39 | 5.94 | 10.82 | 7.20 | 7.74 | 10.44 | 9.05 | 5.66 |
Net Debt/EBITDA |
0.94 | 1.07 | 1.92 | 1.56 | 2.68 | 3.07 | 3.31 | 3.05 | 2.52 | 1.57 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 7.71% | 8.96% | 15.31% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.14 | 0.16 | 0.26 |
Asset Turnover |
0.15 | 0.08 | 0.15 | 0.03 | 0.04 | 0.17 | 0.04 | 0.08 | 0.05 | 0.03 |
Operating CF/Net income |
1.03 | 0.89 | 0.86 | 0.80 | 0.85 | 1.55 | 0.30 | 0.42 | 0.08 | 0.52 |
Capex/Depreciation |
(0.08) | (490.33) | (3.80) | (0.73) | (1.19) | (1.81) | (2.14) | (1.45) | (0.76) | (2.89) |
Interest Coverage |
(25.93) | (114.68) | — | 174.75 | (113.75) | 8.29 | (1,028.63) | 346.73 | (122.63) | 1,567.55 |
| (198.14%) | (98.10%) | (43.17%) | (48.22%) | (40.65%) | (35.36%) | (53.65%) | (49.50%) | (70.22%) | (377.64%) | |
| (60.61%) | (56.40%) | (30.24%) | (36.99%) | (30.80%) | (21.45%) | (28.79%) | (27.71%) | (39.95%) | (51.37%) | |
ROIC |
0.00% | 0.00% | (406.90%) | (860.78%) | (224.39%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(132.07%) | (104.64%) | (52.90%) | (70.60%) | (40.31%) | (30.94%) | (32.25%) | (29.00%) | (35.92%) | (50.00%) |
Average Days of Receivables |
136.70 | 183.73 | 47.59 | 95.27 | 3.82 | 24.33 | 7.43 | 0.34 | 18.05 | 5.31 |
Research and Development Expense of Revenue |
222.00% | 616.60% | 227.40% | 887.57% | 557.89% | 174.13% | 471.96% | 283.85% | 605.76% | 941.33% |
Selling, General and Administrative Expense of Revenue |
123.16% | 222.77% | 89.16% | 358.69% | 298.24% | 74.48% | 314.43% | 172.25% | 367.88% | 764.28% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
24.68% | 66.28% | 25.34% | 148.61% | 169.90% | 25.52% | 132.69% | 83.28% | 170.19% | 280.32% |
Graham Net Nets |
0.03 | 0.78 | 0.25 | 0.35 | 0.21 | 0.06 | 0.15 | 0.18 | 0.12 | 0.17 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(92.20%) | (226.77%) | (20.54%) | (38.03%) | (10.73%) | (2.85%) | (9.08%) | (10.24%) | (8.68%) | (17.78%) |
Free Cash Flow Yield |
(91.01%) | (209.54%) | (18.06%) | (31.31%) | (9.57%) | (4.55%) | (3.16%) | (4.71%) | (0.83%) | (9.78%) |
Revenue per Share |
0.46 | 0.39 | 1.03 | 0.29 | 0.38 | 1.55 | 0.41 | 0.68 | 0.34 | 0.19 |
Operating CF per Share |
(1.86) | (2.55) | (1.74) | (2.58) | (2.42) | (3.07) | (0.81) | (0.97) | (0.23) | (1.56) |
Capex per Share |
0.00 | (0.11) | (0.06) | (0.06) | (0.12) | (0.12) | (0.12) | (0.10) | (0.05) | (0.11) |
Free Cash Flow per Share |
(1.87) | (2.66) | (1.80) | (2.64) | (2.54) | (3.19) | (0.93) | (1.07) | (0.28) | (1.67) |
Cash per Share |
1.65 | 3.28 | 4.25 | 5.01 | 7.39 | 6.86 | 9.15 | 7.83 | 8.16 | 5.75 |
Shareholders Equity per Share |
0.31 | 1.63 | 4.60 | 5.25 | 8.19 | 6.72 | 5.25 | 5.01 | 5.16 | 4.18 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.31 | 1.63 | 4.60 | 5.25 | 8.19 | 6.72 | 5.25 | 5.01 | 5.16 | 4.18 |
Free Cash Flow |
(165.58) | (219.11) | (136.90) | (181.45) | (171.78) | (186.99) | (46.73) | (50.42) | (11.46) | (53.72) |
Working Capital |
117.65 | 212.09 | 277.61 | 296.64 | 460.43 | 360.88 | 403.88 | 338.88 | 295.49 | 154.10 |
Capital Expenditures |
(0.34) | (8.83) | (4.72) | (4.10) | (7.98) | (7.15) | (6.06) | (4.72) | (2.04) | (3.47) |
Net Current Asset Value |
4.65 | 82.00 | 190.77 | 203.11 | 383.47 | 240.07 | 217.40 | 190.55 | 167.02 | 92.61 |
EV/EBIT |
0.00 | 0.53 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.01 | 0.27 | 0.06 | 0.21 | 0.31 | 0.08 | 0.30 | 0.15 | 0.15 | 0.57 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
1.24 | 0.00 | 0.10 | 0.36 | 0.39 | 0.28 | 0.26 | 0.08 | 0.07 | 0.03 |
Cash ROIC |
(95.20%) | (54.21%) | (20.37%) | (25.74%) | (16.31%) | (23.50%) | (6.49%) | (7.91%) | (2.01%) | (15.13%) |
Accounts Receivable Turnover |
2.58 | 2.44 | 10.19 | 7.28 | 8.09 | 28.06 | 91.66 | 90.09 | 35.80 | 10.94 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
Average Receivables |
15.72 | 13.23 | 7.67 | 2.71 | 3.16 | 3.23 | 0.22 | 0.35 | 0.38 | 0.55 |
Average Payables |
4.05 | 6.88 | 8.89 | 7.28 | 5.73 | 6.13 | 5.59 | 4.67 | 4.33 | 3.01 |
Average Assets |
264.06 | 420.37 | 506.74 | 595.90 | 625.04 | 540.74 | 464.64 | 396.82 | 301.22 | 189.27 |
Average Common Equity |
80.78 | 241.69 | 354.89 | 457.16 | 473.61 | 328.01 | 249.30 | 222.12 | 171.34 | 25.75 |
Columns are period end dates